129 related articles for article (PubMed ID: 27815358)
1. Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors.
Infante JR; Hollebecque A; Postel-Vinay S; Bauer TM; Blackwood EM; Evangelista M; Mahrus S; Peale FV; Lu X; Sahasranaman S; Zhu R; Chen Y; Ding X; Murray ER; Schutzman JL; Lauchle JO; Soria JC; LoRusso PM
Clin Cancer Res; 2017 May; 23(10):2423-2432. PubMed ID: 27815358
[No Abstract] [Full Text] [Related]
2. Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
Italiano A; Infante JR; Shapiro GI; Moore KN; LoRusso PM; Hamilton E; Cousin S; Toulmonde M; Postel-Vinay S; Tolaney S; Blackwood EM; Mahrus S; Peale FV; Lu X; Moein A; Epler J; DuPree K; Tagen M; Murray ER; Schutzman JL; Lauchle JO; Hollebecque A; Soria JC
Ann Oncol; 2018 May; 29(5):1304-1311. PubMed ID: 29788155
[TBL] [Abstract][Full Text] [Related]
3. A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
Chow LQ; Eckhardt SG; O'Bryant CL; Schultz MK; Morrow M; Grolnic S; Basche M; Gore L
Cancer Chemother Pharmacol; 2008 Sep; 62(4):631-46. PubMed ID: 18058098
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.
Sausville E; Lorusso P; Carducci M; Carter J; Quinn MF; Malburg L; Azad N; Cosgrove D; Knight R; Barker P; Zabludoff S; Agbo F; Oakes P; Senderowicz A
Cancer Chemother Pharmacol; 2014 Mar; 73(3):539-49. PubMed ID: 24448638
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.
Mettu NB; Niedzwiecki D; Rushing C; Nixon AB; Jia J; Haley S; Honeycutt W; Hurwitz H; Bendell JC; Uronis H
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1025-1035. PubMed ID: 30895346
[TBL] [Abstract][Full Text] [Related]
6. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
Tan AR; Wright GS; Thummala AR; Danso MA; Popovic L; Pluard TJ; Han HS; Vojnović Ž; Vasev N; Ma L; Richards DA; Wilks ST; Milenković D; Yang Z; Antal JM; Morris SR; O'Shaughnessy J
Lancet Oncol; 2019 Nov; 20(11):1587-1601. PubMed ID: 31575503
[TBL] [Abstract][Full Text] [Related]
7. Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.
Leijen S; van Geel RM; Pavlick AC; Tibes R; Rosen L; Razak AR; Lam R; Demuth T; Rose S; Lee MA; Freshwater T; Shumway S; Liang LW; Oza AM; Schellens JH; Shapiro GI
J Clin Oncol; 2016 Dec; 34(36):4371-4380. PubMed ID: 27601554
[TBL] [Abstract][Full Text] [Related]
8. Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.
Aspeslagh S; Stein M; Bahleda R; Hollebecque A; Salles G; Gyan E; Fudio S; Extremera S; Alfaro V; Soto-Matos A; Soria JC
Anticancer Drugs; 2017 Mar; 28(3):341-349. PubMed ID: 27977433
[TBL] [Abstract][Full Text] [Related]
9. Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours.
Seto T; Esaki T; Hirai F; Arita S; Nosaki K; Makiyama A; Kometani T; Fujimoto C; Hamatake M; Takeoka H; Agbo F; Shi X
Cancer Chemother Pharmacol; 2013 Sep; 72(3):619-27. PubMed ID: 23892959
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.
Hu XC; Zhang J; Xu BH; Cai L; Ragaz J; Wang ZH; Wang BY; Teng YE; Tong ZS; Pan YY; Yin YM; Wu CP; Jiang ZF; Wang XJ; Lou GY; Liu DG; Feng JF; Luo JF; Sun K; Gu YJ; Wu J; Shao ZM
Lancet Oncol; 2015 Apr; 16(4):436-46. PubMed ID: 25795409
[TBL] [Abstract][Full Text] [Related]
11. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
12. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP
Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572
[TBL] [Abstract][Full Text] [Related]
13. Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors.
Calvo E; Braiteh F; Von Hoff D; McWilliams R; Becerra C; Galsky MD; Jameson G; Lin J; McKane S; Wickremsinhe ER; Hynes SM; Bence Lin A; Hurt K; Richards D
Oncology; 2016; 91(5):251-260. PubMed ID: 27598338
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.
Angevin E; Cassier PA; Italiano A; Gonçalves A; Gazzah A; Terret C; Toulmonde M; Gravis G; Varga A; Parlavecchio C; Paci A; Poinsignon V; Soria JC; Drubay D; Hollebecque A
Eur J Cancer; 2017 Sep; 83():194-202. PubMed ID: 28750271
[TBL] [Abstract][Full Text] [Related]
15. CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications.
Laroche-Clary A; Lucchesi C; Rey C; Verbeke S; Bourdon A; Chaire V; Algéo MP; Cousin S; Toulmonde M; Vélasco V; Shutzman J; Savina A; Le Loarer F; Italiano A
Ann Oncol; 2018 Apr; 29(4):1023-1029. PubMed ID: 29409053
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors.
Fountzilas C; Adjei A; Opyrchal M; Evans R; Ghasemi M; Attwood K; Groman A; Bshara W; Goey A; Wilton J; Ma WW; Iyer R
Int J Cancer; 2021 Dec; 149(12):2063-2074. PubMed ID: 34319586
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.
Daud AI; Ashworth MT; Strosberg J; Goldman JW; Mendelson D; Springett G; Venook AP; Loechner S; Rosen LS; Shanahan F; Parry D; Shumway S; Grabowsky JA; Freshwater T; Sorge C; Kang SP; Isaacs R; Munster PN
J Clin Oncol; 2015 Mar; 33(9):1060-6. PubMed ID: 25605849
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.
Mortazavi A; Ling Y; Martin LK; Wei L; Phelps MA; Liu Z; Harper EJ; Ivy SP; Wu X; Zhou BS; Liu X; Deam D; Monk JP; Hicks WJ; Yen Y; Otterson GA; Grever MR; Bekaii-Saab T
Invest New Drugs; 2013 Jun; 31(3):685-95. PubMed ID: 22847785
[TBL] [Abstract][Full Text] [Related]
19. A phase I pharmacokinetic and pharmacodynamic study of GTI-2040 in combination with gemcitabine in patients with solid tumors.
Malik L; Zwiebel A; Cooper J
Cancer Chemother Pharmacol; 2018 Sep; 82(3):533-539. PubMed ID: 30022224
[TBL] [Abstract][Full Text] [Related]
20. A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
Shapiro GI; LoRusso P; Cho DC; Musib L; Yan Y; Wongchenko M; Chang I; Patel P; Chan IT; Sanabria-Bohorquez S; Meng RD; Bendell JC
Invest New Drugs; 2021 Feb; 39(1):163-174. PubMed ID: 32737717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
